Pharmaceuticals, Biotechnology & Life Sciences

Explore the $400 billion AstraZeneca‑BMS merger: how it could reshape oncology, boost R&D, and challenge regulators while reshaping patient access and healthcare costs.

Neurocrine Biosciences Q2 earnings beat forecasts, boosting Ingrezza guidance and attracting analyst upgrades – a bright outlook amid insider sales.

Vertex’s Q2 2026 earnings preview: deep dive into CF revenue trends, margin outlook, and next‑gen therapies that could shape the specialty pharma market.

Explore how a potential merger between AstraZeneca and Bristol‑Myers Squibb could reshape oncology, R&D and global market reach, boosting investor value and industry dynamics.

Discover why investors are watching Pfizer’s upcoming earnings, from revenue trends to oncology growth, and how it signals the health of the pharma sector.

New Nordisk’s pivotal earnings week: after a ZEUS flop, the firm ramps up 2026 capacity, boosts revenue outlook and holds the wheel of its GLP‑1 leaders, Wegovy & Ozempic.

West Pharmaceutical Services cyber‑breach reveals the growing risk to pharma data security—why operational resilience, IP protection, and strategic M&A matter for industry survival.

Investors eye Bristol‑Myers Squibb as a low‑beta, steady‑growth pharma stock—balanced legacy revenue, hefty R&D, and a growing oncology pipeline amid tech‑driven market swings.

Illumina Q2 2026: solid revenue growth, disciplined costs, and a SomaLogic acquisition that expands multi‑omics capabilities, strengthening its competitive edge in life‑sciences.

Neurocrine Biosciences posts Q2 2026 growth, Ingrezza revenue boost, and strategic equity moves—highlighting solid performance and a bullish outlook.